Statin treatment and new-onset diabetes: A review of proposed mechanisms

Metabolism: Clinical and Experimental

Volumn 63, Issue 6, 2014, Pages 735-745

  Brault, Marilyne ^a   Ray, Jessica ^b   Gomez, Yessica Haydee ^a   Mantzoros, Christos S ^c   Daskalopoulou, Stella S ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adipocytes; Adiponectin; Cholesterol; Diabetes mellitus; GLUT4; HMG CoA inhibitors; Isoprenoids; Lipophilicity

Indexed keywords

ADIPONECTIN; CALCIUM CHANNEL; CAVEOLIN; CCAAT ENHANCER BINDING PROTEIN; DOLICHOL; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GLUCOSE TRANSPORTER 4; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN RECEPTOR SUBSTRATE; ISOPRENOID; LEPTIN; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAB PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UBIDECARENONE; UNCOUPLING PROTEIN 3;

ADIPOCYTE; BIOSYNTHESIS; CALCIUM CELL LEVEL; CALCIUM DEPLETION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYDROPHILICITY; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPOPHILICITY; META ANALYSIS (TOPIC); NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT RISK; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADIPOCYTES; ADIPONECTIN; CA(2+) CHANNELS; CHOLESTEROL; DIABETES MELLITUS; GLUT4; HMG-COA INHIBITORS; ISOPRENOIDS; LIPOPHILICITY;

ADIPOCYTES; ADIPONECTIN; ANIMALS; CALCIUM CHANNELS; CAVEOLINS; CELL DIFFERENTIATION; DIABETES MELLITUS; DOLICHOL; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ION CHANNELS; LEPTIN; MICRORNAS; MITOCHONDRIAL PROTEINS; TERPENES; UBIQUINONE;

EID: 84901200014     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.02.014     Document Type: Review

References (98)

1. Global status report on noncommunicable diseases 2010 2011 World Health Organization Geneva
2. S. Mendis The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective Prog Cardiovasc Dis 53 1 2010 10 14
3. F. Taylor, M.D. Huffman, and A.F. Macedo et al. Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
4. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 23 Suppl 1 2004 III39 III43
5. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 23 Suppl 1 2004 III-50 III-57
6. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
7. D.J. Freeman, J. Norrie, and N. Sattar et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 3 2001 357 362
8. A.A. Carter, T. Gomes, and X. Camacho et al. Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610
9. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 9716 2010 735 742
10. E.P. Navarese, A. Buffon, and F. Andreotti et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus Am J Cardiol 111 8 2013 1123 1130
11. W.L. Baker, R. Talati, and C.M. White et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis Diabetes Res Clin Pract 87 1 2010 98 107
12. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs 2012 US Food and Drug Administration
13. D.D. Waters, J.E. Ho, and D.A. DeMicco et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 14 2011 1535 1545
14. K. Axsom, J.S. Berger, and A.Z. Schwartzbard Statins and diabetes: the good, the bad, and the unknown Curr Atheroscler Rep 15 2 2013 299
15. N. Sattar, and M.R. Taskinen Statins are diabetogenic - myth or reality? Atheroscler Suppl 13 1 2012 1 10
16. A. Bergdahl, E. Persson, and P. Hellstrand et al. Lovastatin induces relaxation and inhibits L-type Ca2 + current in the rat basilar artery Pharmacol Toxicol 93 3 2003 128 134
17. S.A. Mortensen, A. Leth, and E. Agner et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors Mol Aspects Med 18 Supplement 1 1997 137 144 (0)
18. J.J.V. McMurray, P. Dunselman, and H. Wedel et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) J Am Coll Cardiol 56 15 2010 1196 1204
19. D. Williams, and J. Feely Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacokinet 41 5 2002 343 370
20. H. Fujino, I. Yamada, and J. Kojima et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human Drug Metab Pharmacokinet 14 6 1999 415 424
21. T. Sakaeda, H. Fujino, and C. Komoto et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport Pharm Res 23 3 2006 506 512
22. J.L. Goldstein, and M.S. Brown The low-density lipoprotein pathway and its relation to atherosclerosis Annu Rev Biochem 46 1977 897 930
23. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 1 2005 117 125
24. Y. Shitara, and Y. Sugiyama Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 1 2006 71 105
25. T. Yada, M. Nakata, and T. Shiraishi et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2 + signalling and insulin secretion due to blockade of L-type Ca2 + channels in rat islet beta-cells Br J Pharmacol 126 5 1999 1205 1213
26. F. Xia, L. Xie, and A. Mihic et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells Endocrinology 149 10 2008 5136 5145
27. M. Ishikawa, F. Okajima, and N. Inoue et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a β-cell line, MIN6 cells J Atheroscler Thromb 13 6 2006 329 335
28. M. Tsuchiya, M. Hosaka, and T. Moriguchi et al. Cholesterol biosynthesis pathway intermediates and inhibitors regulate glucose-stimulated insulin secretion and secretory granule formation in pancreatic β-cells Endocrinology 151 10 2010 4705 4716
29. T. Mita, H. Watada, and S. Nakayama et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia Endocr J 54 3 2007 441 447
30. A.H. Khan, and J.E. Pessin Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways Diabetologia 45 11 2002 1475 1483
31. M. Nakata, S. Nagasaka, and I. Kusaka et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control Diabetologia 49 8 2006 1881 1892
32. A.W. Cohen, T.P. Combs, and P.E. Scherer et al. Role of caveolin and caveolae in insulin signaling and diabetes Am J Physiol Endocrinol Metab 285 6 2003 E1151 E1160
33. J. Gustavsson, S. Parpal, and P. Stralfors Insulin-stimulated glucose uptake involves the transition of glucose transporters to a caveolae-rich fraction within the plasma membrane: implications for type II diabetes Mol Med 2 3 1996 367 372
34. T. Khan, M.P. Hamilton, and D.I. Mundy et al. Impact of simvastatin on adipose tissue: pleiotropic effects in vivo Endocrinology 150 12 2009 5262 5272
35. A. Takaguri, K. Satoh, and M. Itagaki et al. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes J Pharmacol Sci 107 1 2008 80 89
36. E.D. Abel, O. Peroni, and J.K. Kim et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver Nature 409 6821 2001 729 733
37. T.F. McGuire, X.Q. Xu, and S.J. Corey et al. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity Biochem Biophys Res Commun 204 1 1994 399 406
38. M. Cormont, M.N. Bortoluzzi, and N. Gautier et al. Potential role of Rab4 in the regulation of subcellular localization of Glut4 in adipocytes Mol Cell Biol 16 12 1996 6879 6886
39. H. Shibata, W. Omata, and Y. Suzuki et al. A synthetic peptide corresponding to the Rab4 hypervariable carboxyl-terminal domain inhibits insulin action on glucose transport in rat adipocytes J Biol Chem 271 16 1996 9704 9709
40. B.T. Kinsella, and W.A. Maltese rab GTP-binding proteins with three different carboxyl-terminal cysteine motifs are modified in vivo by 20-carbon isoprenoids J Biol Chem 267 6 1992 3940 3945
41. T. Kadowaki, K. Hara, and T. Yamauchi et al. Molecular mechanism of insulin resistance and obesity Exp Biol Med 228 10 2003 1111 1117
42. N. Kubota, Y. Terauchi, and H. Miki et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance Mol Cell 4 4 1999 597 609
43. Z. Wu, E.D. Rosen, and R. Brun et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity Mol Cell 3 2 1999 151 158
44. A.C. Nicholson, D.P. Hajjar, and X. Zhou et al. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression Br J Pharmacol 151 6 2007 807 815
45. Y. Ishihara, K. Ohmori, and M. Mizukawa et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice Atherosclerosis 212 1 2010 131 138
46. L.H. Chamberlain Inhibition of isoprenoid biosynthesis causes insulin resistance in 3 T3-L1 adipocytes FEBS Lett 507 3 2001 357 361
47. K.W. Siddals, E. Marshman, and M. Westwood et al. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways J Biol Chem 279 37 2004 38353 38359
48. T. Goto, H. Nagai, and K. Egawa et al. Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARgamma agonist Biochem J 438 1 2011 111 119
49. M. Carlberg, A. Dricu, and H. Blegen et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface: evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth J Biol Chem 271 29 1996 17453 17462
50. C.P. Ciosek Jr., D.R. Magnin, and T.W. Harrity et al. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo J Biol Chem 268 33 1993 24832 24837
51. F.M. Ashcroft, P. Proks, and P.A. Smith et al. Stimulus-secretion coupling in pancreatic β cells J Cell Biochem 55 S1994A 1994 54 65
52. K. Folkers, P. Langsjoen, and R. Willis et al. Lovastatin decreases coenzyme Q levels in humans Proc Natl Acad Sci U S A 87 22 1990 8931 8934
53. S. Ganesan, and M.K. Ito Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3 T3-L1 adipocytes Metab Syndr Relat Disord 11 4 2013 251 255
54. S. Le Lay, S. Krief, and C. Farnier et al. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes J Biol Chem 276 20 2001 16904 16910
55. H. Wang, A.X. Wang, and E.J. Barrett Caveolin-1 is required for vascular endothelial insulin uptake Am J Physiol Endocrinol Metab 300 1 2011 E134 E144
56. O. Feron, C. Dessy, and J.P. Desager et al. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance Circulation 103 1 2001 113 118
57. N. Maeda, I. Shimomura, and K. Kishida et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat Med 8 7 2002 731 737
58. H. Kondo, I. Shimomura, and Y. Matsukawa et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome Diabetes 51 7 2002 2325 2328
59. N. Vionnet, E.H. Hani, and S. Dupont et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24 Am J Hum Genet 67 6 2000 1470 1480
60. D. Wanders, E.P. Plaisance, and R.L. Judd Lipid-lowering drugs and circulating adiponectin Vitam Horm 90 2012 341 374
61. T. Forst, A. Pfützner, and G. Lübben et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study Metabolism 56 4 2007 491 496
62. K.K. Koh, M.J. Quon, and S.H. Han et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients Diabetes Care 31 4 2008 776 782
63. K.K. Koh, M.J. Quon, and I. Sakuma et al. Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia Int J Cardiol 146 3 2011 434 437
64. T. Nakamura, Y. Kodama, and H. Takano et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia Atherosclerosis 193 2 2007 449 451
65. S. Nomura, A. Shouzu, and S. Omoto et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients Blood Coagul Fibrinolysis 20 6 2009 440 447
66. K. Sakamoto, T. Sakamoto, and H. Ogawa et al. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study Clin Ther 28 7 2006 1012 1021
67. H.Y. Qu, Y.W. Xiao, and G.H. Jiang et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia Pharm Res 26 4 2009 958 964
68. P. Anagnostis, D. Selalmatzidou, and M. Sapranidis et al. Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: a prospective study Indian J Endocrinol Metab 16 1 2012 146 147
69. M.-H. Gannagé-Yared, R.R. Azar, and M. Amm-Azar et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients Metabolism 54 7 2005 947 951
70. M. Chetboun, G. Abitbol, and K. Rozenberg et al. Maintenance of redox state and pancreatic beta-cell function: role of leptin and adiponectin J Cell Biochem 113 6 2012 1966 1976
71. T. Maeda, and N. Horiuchi Simvastatin suppresses leptin expression in 3 T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation J Biochem 145 6 2009 771 781
72. S.P. Zhao, and Z.H. Wu Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits Clin Chim Acta 360 1-2 2005 133 140
73. Y.-M. Sun, J. Li, and Y. Luan et al. Effect of statin therapy on leptin levels in patients with coronary heart disease Peptides 31 6 2010 1205 1207
74. A. Bellia, S. Rizza, and M.F. Lombardo et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy Atherosclerosis 223 1 2012 197 203
75. H. Ohbayashi Pitavastatin improves serum resistin levels in patients with hypercholesterolemia J Atheroscler Thromb 15 2 2008 87 93
76. P. Schrauwen, W.H. Saris, and M.K. Hesselink An alternative function for human uncoupling protein 3: protection of mitochondria against accumulation of nonesterified fatty acids inside the mitochondrial matrix FASEB J 15 13 2001 2497 2502
77. 1H NMR spectroscopy study Diabetologia 42 1 1999 113 116
78. C. Moro, S. Bajpeyi, and S.R. Smith Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity Am J Physiol Endocrinol Metab 294 2 2008 E203 E213
79. D.A. Pan, S. Lillioja, and A.D. Kriketos et al. Skeletal muscle triglyceride levels are inversely related to insulin action Diabetes 46 6 1997 983 988
80. S. Larsen, N. Stride, and M. Hey-Mogensen et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance J Am Coll Cardiol 61 1 2013 44 53
81. M.D. Williams, and G.M. Mitchell MicroRNAs in insulin resistance and obesity Exp Diabetes Res 2012 2012 484696
82. K.J. Rayner, Y. Suarez, and A. Davalos et al. MiR-33 contributes to the regulation of cholesterol homeostasis Science 328 5985 2010 1570 1573
83. N. Wijesekara, L.H. Zhang, and M.H. Kang et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets Diabetes 61 3 2012 653 658
84. L.R. Brunham, J.K. Kruit, and T.D. Pape et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment Nat Med 13 3 2007 340 347
85. J.K. Kruit, N. Wijesekara, and J.E. Fox et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules Diabetes 60 12 2011 3186 3196
86. A.K. Lee, V. Yeung-Yam-Wah, and F.W. Tse et al. Cholesterol elevation impairs glucose-stimulated Ca(2 +) signaling in mouse pancreatic -cells Endocrinology 152 9 2011 3351 3361
87. R.M. Allen, T.J. Marquart, and C.J. Albert et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity EMBO Mol Med 4 9 2012 882 895
88. C. Baigent, A. Keech, and P.M. Kearney et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278
89. J.C. LaRosa, J. He, and S. Vupputuri Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 24 1999 2340 2346
90. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 7404 2003 1423
91. P. Jones, S. Kafonek, and I. Laurora et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 5 1998 582 587
92. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2 2000 207 213
93. L. Ose, D. Budinski, and N. Hounslow et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia Curr Med Res Opin 25 11 2009 2755 2764
94. D. Preiss, S. Seshasai, and P. Welsh et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 24 2011 2556 2564
95. J.R. Downs, M. Clearfield, and S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS JAMA 279 20 1998 1615 1622
96. T. Yamakawa, T. Takano, and S. Tanaka et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus J Atheroscler Thromb 15 5 2008 269 275
97. H. Naci, J. Brugts, and T. Ades Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials Circ Cardiovasc Qual Outcomes 6 4 2013 390 399
98. M.S. Brown, and J.L. Goldstein The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor Cell 89 3 1997 331 340